A Phase 3 interventional study of Aripiprazole IM Depot in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 214 sites in 28 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-11-26.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 3rd largest by enrollment of the 125 interventional ones that give a count, is one of 8 that started in 2008, is one of 34 in phase 3, and was the 54th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,081 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 2nd largest by enrollment of the 111 interventional ones that give a count, is one of 4 that started in 2008, is one of 50 in phase 3, and was the 28th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.
This will be an open-label, uncontrolled study which will enroll subjects from Phase 4 of Study 31-07-246 and Phase 3 of Study 31- 07-247 and new subjects not participating in Studies 246/247. The treatment history of subjects prior to enrollment in the open-label study will vary according to the design of the pivotal double-blind study (i.e., 31-07-246 or 31-07-247).
This open-label study will be comprised of phases similar to the pivotal double-blind studies (i.e., Studies 246/247): a screening phase (if applicable), a conversion phase (Phase 1, if applicable), an oral stabilization phase (Phase 2), and an IM depot open-label maintenance phase (Phase 3). Phase 3 will be a 52-week treatment period with a 26-week follow-up period.
During Phase 3 (the open-label maintenance phase) oral aripiprazole rescue medication will be allowed for subjects who do not meet stability criteria or meet the criteria for impending relapse/exacerbation of psychotic symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Treatment of aripiprazole IM depot (300mg or 400mg)
Drug: Aripiprazole IM Depot
300mg or 400mg
Also known as: Oral Aripiprazole
Percentage of Stable Participants at Baseline Who Remained Stable at Endpoint (Last Visit).
"Stable" was defined as meeting all of the following criteria: Outpatient status; Positive and negative syndrome scale (PANSS) total score ≤ 80; Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) ≤ 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2. The percentage of stable participants at baseline who remain stable at endpoint (last visit) is described here.
Time frame: Baseline to Week 52/Last visit
Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.
"Impending relapse criteria" was defined as meeting all the following criteria: 1) Clinical Global Impression of Improvement (CGI-I) ≥ 5 (minimally worse), AND an increase to score of \>4 and absolute increase of ≥ 2 on the individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content); or an increase to score \>4 and absolute increase of ≥ 4 on the combined 4 PANSS items on any of these PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) OR 2) Hospitalization due to worsening of psychotic symptoms, but excluding hospitalization for psychosocial reasons, OR 3) CGI-SS score of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2, OR 4) Violent behavior resulting in clinically relevant self-injury, injury to another person, or property damage.
Time frame: Weeks 2,4,8,12,16,20,24,28,32,36,40,44,48,52, and Last visit (upto 4 weeks ± 3 days after completion or withdrawal)
Percentage of Participants Achieving Remission.
Remission is defined as a score of ≤ 3 on each of the following specific PANSS items, maintained for a period of six months: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, and lack of spontaneity.
Time frame: Overall remission from Weeks 2,4,8,12,16,20,24,28,32,36,40,44,48 and 52
Percentage of Participants Stable at Baseline and Remaining Stable at Week 28.
"Stable" was defined as meeting all of the following criteria: Outpatient status; PANSS total score ≤ 80; Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) ≤ 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2. The percentage of stable participants at baseline who remain stable at Week 28 is described here.
Time frame: Baseline to Week 28
Percentage of Participants With Time to First Exacerbation of Psychotic Symptoms/Impending Relapse.
Participants who first time meet relapse criteria were considered as having an event at date of exacerbation of psychotic symptoms/impending relapse. Time to first event was calculated as the earliest date of meeting one of relapse criteria. Limited concurrent treatment with oral aripiprazole was permitted as rescue therapy.
Time frame: Baseline to Week 52
Mean Change From Baseline to Endpoint (Last Visit) in Positive and Negative Syndrome Scale (PANSS) Total Score.
PANSS total score (range 30-210) is the sum of the rating scores for 7 positive scale items, 7 negative scale items and 16 general psychopathology scale items from the PANSS scale. PANSS positive subscale score (range 7-49) is the sum of the rating scores for the 7 positive scale items from the PANSS scale. PANSS negative subscale score (range 7-49) is the sum of the rating scores for the 7 negative scale items from the PANSS scale. The severity of each scale is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.
Time frame: Baseline, Weeks 12, 24, 52 and last visit
Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score.
To assess CGI-S, the rater or physician will answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Baseline, Weeks 12, 24, 52 and last visit
Mean Change From Baseline to Endpoint in PANSS Positive and Negative Subscales.
PANSS positive subscale score (range 7-49) is the sum of the rating scores for the 7 positive scale items from the PANSS scale. Positive subscale consists of 7 positive symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). PANSS negative subscale score (range 7-49) is the sum of the rating scores for the 7 negative scale items from the PANSS scale. Negative subscale consists of 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). The severity of each scale is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.
Time frame: Baseline, Weeks 12, 24, 52 and last visit
Mean Clinical Global Impression of Improvement (CGI-I) Score.
To assess CGI-I the rater or physician will rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses will be compared to the participants condition at baseline. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Time frame: Weeks 2, 4, 12, 24, 52 and last visit
Percentage of Participants Who Discontinued Due to All Causes.
Participants who discontinued due to any cause were noted. Limited concurrent treatment with oral aripiprazole was permitted as rescue therapy.
Time frame: Baseline to Week 52
This open label Phase 3 study enrolled participants from the maintenance phase of study NCT00705783 (31-07-246) and study NCT00706654 (31-07-247) and new participants. Participants received aripiprazole intramuscular (IM) depot as maintenance treatment.
| Milestone | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Started | 1081 |
| Completed | 858 |
| Not completed | 223 |
| Withdrew: Lost to follow-up | 19 |
| Withdrew: Met withdrawal criteria | 24 |
| Withdrew: Physician decision | 16 |
| Withdrew: Withdrawal by subject | 89 |
| Withdrew: Protocol deviation | 1 |
| Withdrew: Adverse event | 31 |
| Withdrew: Lack of efficacy with ae | 37 |
| Withdrew: Lack of efficacy without ae | 6 |
"Stable" was defined as meeting all of the following criteria: Outpatient status; Positive and negative syndrome scale (PANSS) total score ≤ 80; Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) ≤ 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2. The percentage of stable participants at baseline who remain stable at endpoint (last visit) is described here.
| Percentage of participants | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Baseline (N=1075) | 100 |
| Week 2 (N=1023) | 99.02 |
| Week 4 (N=1045) | 99.14 |
| Week 8 (N=1009) | 98.51 |
| Week 12 (N=988) | 97.47 |
| Week 16 (N=951) | 98.42 |
| Week 20 (N=919) | 98.15 |
| Week 24 (N=880) | 99.20 |
| Week 28 (N=854) | 98.95 |
| Week 32 (N=838) | 99.16 |
| Week 36 (N=814) | 99.26 |
| Week 40 (N=807) | 99.50 |
| Week 44 (N=784) | 99.11 |
| Week 48 (N=751) | 99.20 |
| Week 52 (N=671) | 98.96 |
| Last visit (N=1072) | 94.96 |
"Impending relapse criteria" was defined as meeting all the following criteria: 1) Clinical Global Impression of Improvement (CGI-I) ≥ 5 (minimally worse), AND an increase to score of \>4 and absolute increase of ≥ 2 on the individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content); or an increase to score \>4 and absolute increase of ≥ 4 on the combined 4 PANSS items on any of these PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) OR 2) Hospitalization due to worsening of psychotic symptoms, but excluding hospitalization for psychosocial reasons, OR 3) CGI-SS score of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2, OR 4) Violent behavior resulting in clinically relevant self-injury, injury to another person, or property damage.
| Percentage of participants | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Week 2 (N=1028) | 0.49 |
| Week 4 (N=1049) | 0.48 |
| Week 8 (N=1011) | 0.79 |
| Week 12 (N=988) | 1.52 |
| Week 16 (N=948) | 0.84 |
| Week 20 (N=920) | 1.09 |
| Week 24 (N=883) | 0.45 |
| Week 28 (N=857) | 0.58 |
| Week 32 (N=838) | 0.36 |
| Week 36 (N=814) | 0.25 |
| Week 40 (N=808) | 0.25 |
| Week 44 (N=783) | 0.26 |
| Week 48 (N=750) | 0.27 |
| Week 52 (N=668) | 0.30 |
| Last visit (N=1079) | 4.17 |
| Overall (N=1079) | 8.25 |
Remission is defined as a score of ≤ 3 on each of the following specific PANSS items, maintained for a period of six months: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, and lack of spontaneity.
| Percentage of participants | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Percentage of Participants Achieving Remission. | 51.7 |
"Stable" was defined as meeting all of the following criteria: Outpatient status; PANSS total score ≤ 80; Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) ≤ 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2. The percentage of stable participants at baseline who remain stable at Week 28 is described here.
| Percentage of participants | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Baseline (N=1075) | 100 |
| Week 28 (N=854) | 98.95 |
Participants who first time meet relapse criteria were considered as having an event at date of exacerbation of psychotic symptoms/impending relapse. Time to first event was calculated as the earliest date of meeting one of relapse criteria. Limited concurrent treatment with oral aripiprazole was permitted as rescue therapy.
| Percentage of participants | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Percentage of Participants With Time to First Exacerbation of Psychotic Symptoms/Impending Relapse. | 8.2 |
PANSS total score (range 30-210) is the sum of the rating scores for 7 positive scale items, 7 negative scale items and 16 general psychopathology scale items from the PANSS scale. PANSS positive subscale score (range 7-49) is the sum of the rating scores for the 7 positive scale items from the PANSS scale. PANSS negative subscale score (range 7-49) is the sum of the rating scores for the 7 negative scale items from the PANSS scale. The severity of each scale is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.
| Units on a scale | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Week 12 (N=987) | -1.69 ± 6.21 |
| Week 24 (N=882) | -2.55 ± 7.08 |
| Week 52 (N=669) | -3.55 ± 7.75 |
| Last visit (N=1078) | -1.72 ± 10.21 |
To assess CGI-S, the rater or physician will answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| Units on a scale | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Week 12 (N=987) | -0.11 ± 0.52 |
| Week 24 (N=883) | -0.17 ± 0.53 |
| Week 52 (N=668) | -0.24 ± 0.56 |
| Last visit (N=1079) | -0.14 ± 0.70 |
PANSS positive subscale score (range 7-49) is the sum of the rating scores for the 7 positive scale items from the PANSS scale. Positive subscale consists of 7 positive symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). PANSS negative subscale score (range 7-49) is the sum of the rating scores for the 7 negative scale items from the PANSS scale. Negative subscale consists of 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). The severity of each scale is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.
| Units on a scale | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Week 12 positive subscale score (N=987) | -0.42 ± 2.11 |
| Week 24 positive subscale score (N=882) | -0.68 ± 2.26 |
| Week 52 positive subscale score (N=669) | -1.04 ± 2.53 |
| Last visit positive subscale score (N=1078) | -0.49 ± 3.38 |
| Week 12 negative subscale score (N=987) | -0.40 ± 2.40 |
| Week 24 negative subscale score (N=882) | -0.53 ± 2.52 |
| Week 52 negative subscale score (N=669) | -0.80 ± 2.94 |
| Last visit negative subscale score (N=1078) | -0.46 ± 3.19 |
To assess CGI-I the rater or physician will rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses will be compared to the participants condition at baseline. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
| Units on a scale | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Baseline (N=1081) | 3.48 ± 0.82 |
| Week 2 (N=1026) | 3.52 ± 0.85 |
| Week 4 (N=1049) | 3.49 ± 0.86 |
| Week 12 (N=987) | 3.42 ± 0.92 |
| Week 24 (N=882) | 3.33 ± 0.98 |
| Week 52 (N=669) | 3.25 ± 0.99 |
| Last visit (N=1079) | 3.35 ± 1.10 |
Participants who discontinued due to any cause were noted. Limited concurrent treatment with oral aripiprazole was permitted as rescue therapy.
| Percentage of participants | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Percentage of Participants Who Discontinued Due to All Causes. | 20.6 |
Collected over Phase 3 Week 1 to Week 52/Early termination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole 400/300 mg IM Depot | — | 95/1,081 (8.8%) | 254/1,081 (23.5%) |
| Event | Aripiprazole 400/300 mg IM Depot |
|---|---|
| SchizophreniaPsychiatric disorders | 21/1081 |
| Psychotic disorderPsychiatric disorders | 15/1081 |
| Schizophrenia, paranoid typePsychiatric disorders | 5/1081 |
| PneumoniaInfections and infestations | 4/1081 |
| Suicide attemptPsychiatric disorders | 3/1081 |
| Myocardial infarctionCardiac disorders | 2/1081 |
| CholelithiasisHepatobiliary disorders | 2/1081 |
| BronchitisInfections and infestations | 2/1081 |
| CellulitisInfections and infestations | 2/1081 |
| Intentional overdoseInjury, poisoning and procedural complications | 2/1081 |
| Event | Aripiprazole 400/300 mg IM Depot |
|---|---|
| HeadacheNervous system disorders | 82/1081 |
| NasopharyngitisInfections and infestations | 76/1081 |
| AnxietyPsychiatric disorders | 73/1081 |
| InsomniaPsychiatric disorders | 71/1081 |
| Age, Continuous(Years) | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Mean | 41.2 ± 10.6 |
| Sex: Female, Male(Participants) | Aripiprazole 400/300 mg IM Depot |
|---|---|
| Female | 439 |
| Male | 642 |
Showing the first 100 of 214 sites across 28 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2008, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →